Anti-CD340/ERBB2/HER2 scFV Antibody (SAA2245) from ProteoGenix; catalogue ARO-A22636; research use only.
Know who made it. See the evidence. Buy through one marketplace.
The Anti-CD340/ERBB2/HER2 scFV Antibody (SAA2245) is a highly specific and potent monoclonal antibody designed for use in biotech research. This antibody targets the CD340/ERBB2/HER2 protein, a member of the epidermal growth factor receptor family, which is overexpressed in many types of cancer cells.
The Anti-CD340/ERBB2/HER2 scFV Antibody (SAA2245) binds to the extracellular domain of the CD340/ERBB2/HER2 protein, blocking its signaling pathways and inhibiting cell growth and proliferation. This antibody has been extensively validated for its high affinity, specificity, and low cross-reactivity with other proteins, making it a reliable tool for studying the function of CD340/ERBB2/HER2 in various biological processes.
The Anti-CD340/ERBB2/HER2 scFV Antibody (SAA2245) is a valuable tool for cancer research, specifically in the study of HER2-positive tumors. It can be used in various applications, including Western blotting, immunoprecipitation, and flow cytometry, to detect and quantify the expression of CD340/ERBB2/HER2 in different cell types and tissues. This antibody can also be used in functional studies to investigate the role of CD340/ERBB2/HER2 in cancer progression and drug resistance.
The Anti-CD340/ERBB2/HER2 scFV Antibody (SAA2245) has been successfully used in several experimental studies. In a recent study, it was used to detect the expression of CD340/ERBB2/HER2 in breast cancer cell lines and patient samples, providing valuable insights into the role of this protein in breast cancer development and progression. Another study used this antibody to investigate the efficacy of a novel HER2-targeted therapy in HER2-positive gastric cancer cells. These examples demonstrate the versatility and reliability of the Anti-CD340/ERBB2/HER2 scFV Antibody (SAA2245) in various experimental settings.
In summary, the Anti-CD340/ERBB2/HER2 scFV Antibody (SAA2245) is a highly specific and potent tool for studying the function of CD340/ERBB2/HER2 in cancer. With its validated performance and wide range of applications, this antibody is a valuable addition to any biotech research arsenal. Order now and discover the potential of CD340/ERBB2/HER2 in cancer biology.
ProteoGenix catalogue number ARO-A22636. For research use only.
Target: CD340/ERBB2/HER2; Clonality: Monoclonal Antibody; Applications: ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| CD340/ERBB2/HER2 |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
